ReviewBlood reviews2015
"No donor"? Consider a haploidentical transplant.
Review in Blood reviews, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05968170 (A Feasibility Study Using the CliniMACS® Device for T-Cell Receptor), which is not on this map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Feasibility Study Using the CliniMACS® Device for T-Cell Receptor (TCR) αβ+CD3+/CD19+ Depleted Hematopoietic Stem Cells for Patients Undergoing Transplant
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Impact of HLA-B leader matching on clinical outcomes of haploidentical hematopoietic stem cell transplantation in adult patients with acute leukemia, a retrospective cohort study.Annals of medicine and surgery (2012) · 2026Article
- The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia.Leukemia · 2025Review
- Article
- "Incidence and significance of donor-specific antibodies in haploidentical stem cell transplantation".Bone marrow transplantation · 2023Article
- Number of HLA-Mismatched Eplets Is Not Associated with Major Outcomes in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: A Center for International Blood and Marrow Transplant Research Study.Transplantation and cellular therapy · 2022Article
- Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia.Frontiers in immunology · 2022Article
- Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy.Frontiers in immunology · 2022Article
- Treatment of allosensitized patients receiving allogeneic transplantation.Blood advances · 2021Article
- Molecular disparity in human leukocyte antigens is associated with outcomes in haploidentical stem cell transplantation.Blood advances · 2020Article
- Article
- Low incidence of hemorrhagic cystitis following ex vivo T-cell depleted haploidentical hematopoietic cell transplantation in children.Bone marrow transplantation · 2020Article
- Article
- Donor-derived CD4Bone marrow transplantation · 2019Article
- High-resolution HLA phased haplotype frequencies to predict the success of unrelated donor searches and clinical outcome following hematopoietic stem cell transplantation.Bone marrow transplantation · 2019Article
- Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation.Frontiers of medicine · 2019Review
- Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.Frontiers in immunology · 2019Review
- Review of Haploidentical Hematopoietic Cell Transplantation.Journal of global oncology · 2018Review
- Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation.Nature communications · 2018Article
- Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia.Bone marrow transplantation · 2017Article
- Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.Journal of hematology & oncology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Haploidentical stem cell transplantation (HaploSCT) is an attractive option for patients requiring a hematopoietic stem cell transplant who do not have an HLA-matched donor, because it is cheaper, can be performed faster, and may extend transplantation to virtually all patients in need. Significant advances have been made in the recent decade with dramatic improvement in treatment outcomes. Historically, overcoming the HLA-incompatibility barrier has been a significant limitation to the expansion of this form of transplant. While ex vivo T-cell depletion effectively prevented the development of acute GVHD, it was associated with a higher treatment-related mortality, in excess of 40% in some series, due to a significant delay in recovery of the adaptive immune system. Newer methods have successfully maintained the memory T cells in the graft and/or selectively depleted alloreactive T cells, and are associated with improved treatment outcomes. Post-transplant cyclophosphamide for GVHD prevention has proven very effective in controlling GVHD with lower incidence of infectious complications and treatment-related mortality-as low as 7% at 1 year-and has become the new standard in how this transplant is performed. Here, we reviewed the current experience with this approach and various other strategies employed to control alloreactivity in this setting, including selective depletion of T cells from the graft, as well as we discuss post-transplantation therapy to prevent disease relapse and improve immunologic reconstitution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.